The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10740 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

NOT Open Access | Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters

December 10, 2020 - 09:59 -- NOT Open Access
Author(s): 
Rendic SP, Guengerich FP
Reference: 
Curr Drug Metab. 2020 Dec 8

In clinical practice chloroquine and hydroxychloroquine are often co-administered with other drugs in the treatment of malaria, chronic inflammatory diseases, and COVID-19. Therefore, their metabolic properties and the effects on activity of cytochrome P450 (P450, CYP) enzymes and drug transporters should be considered into when developing the most efficient treatments for patients.

NOT Open Access | Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19

December 8, 2020 - 10:42 -- NOT Open Access
Author(s): 
Uzun T, Toptaş O, Aydın Türkoğlu Ş
Reference: 
ACS Chem Neurosci. 2020 Dec 3

Artesunate is a safe noncytotoxic drug with low side effects which is used in the treatment of chloroquine-resistant malaria. In addition to being an antimalarial drug, artesunate also has immunomodulatory, anticarcinogenic, and antiviral activity. There are in vivo and in vitro studies reporting that artesunate may have a positive effect on the treatment of COVID-19.

Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020

December 2, 2020 - 09:55 -- Open Access
Author(s): 
Bienvenu AL, Marty AM, Jones MK, Picot S
Reference: 
One Health. 2020 Dec;10:100141

In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends.

Digitalized mass distribution campaign of insecticide-treated nets (ITNs) in the particular context of Covid-19 pandemic in Benin: challenges and lessons learned

November 25, 2020 - 12:47 -- Open Access
Author(s): 
Rock Aïkpon, Cyriaque Affoukou, Aurore Ogouyemi Hounto, et al.
Reference: 
Malaria Journal 2020 19:431, 25 November 2020

In 2020, Benin has implemented a digitalized mass distribution campaign of insecticide-treated nets (ITNs) in the particular context of COVID-19 pandemic. This paper describes the implementation process as well as the challenges and lessons learned from this campaign.

SARS-COV2 and P. falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt

November 25, 2020 - 12:39 -- Open Access
Author(s): 
Iesa MA, Osman ME, Hassan MA, Dirar AI, Abuzeid N, Mancuso JJ, Pandey R, Mohammed AA, Borad MJ, Babiker HM, Konozy EH
Reference: 
New Microbes New Infect. 2020 Nov 19:100817

COVID-19 has caused significant morbidity and mortality, and new cases are on the rise globally, yet malaria-endemic areas report statistically significant lower incidences. We identified potential shared targets for an immune response to SARS-CoV-2 by immune determinants shared identities with Plasmodium falciparum using IEDB's Immune browser tool 9.0.

Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science

November 19, 2020 - 13:23 -- Open Access
Author(s): 
Berlivet L, Löwy I
Reference: 
Med Anthropol Q. 2020 Nov 18

The claim that anti-malaria drugs, chloroquine and hydroxychloroquine, can cure COVID-19 became a focus of fierce political battles that pitted promoters of these pharmaceuticals, Presidents Bolsonaro and Trump among them, against "medical elites." At the center of these battles are different meanings of effectiveness in medicine, the complex role of randomized clinical trials (RCTs) in proving such effectiveness, the task of medical experts and the state in regulating pharmaceuticals, patients' activism, and the collective production of medical knowledge.

Study design and operational framework for a community-based Malaria Elimination Demonstration Project (MEDP) in 1233 villages of district Mandla, Madhya Pradesh

November 17, 2020 - 13:20 -- Open Access
Author(s): 
Harsh Rajvanshi, Praveen K. Bharti, Altaf A. Lal, et al.
Reference: 
Malaria Journal 2020 19:410, 16 November 2020

In the past decade substantial reduction in malaria morbidity and mortality has been observed through well-implemented case management and vector control strategies. India has also achieved a significant reduction in malaria burden in 2018 and has committed to eliminate malaria by 2030. The Mandla Malaria Elimination Demonstration Project (MEDP) was started in 2017 in 1233 villages of District Mandla to demonstrate malaria elimination in a tribal district with hard-to-reach areas was possible using active and passive surveillance, case management, vector control, and targeted information, education and communication campaigns. An operational plan was developed to strengthen the existing surveillance and malaria elimination systems, through fortnightly active case detection to ensure that all cases including those that are introduced into the communities are rapidly identified and treated promptly. The plan also focused on the reduction of human-mosquito contact through the use of Long-Lasting Insecticial Nets (LLINs) and Indoor Residual Spray (IRS). The operational plan was modified in view of the present COVID-19 pandemic by creating systems of assistance for the local administration for COVID-related work while ensuring the operational integrity of malaria elimination efforts.

No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency

November 4, 2020 - 16:10 -- Open Access
Author(s): 
Schilling WHK, Bancone G, White NJ
Reference: 
Blood Cells Mol Dis. 2020 Nov;85:102484

Hydroxychloroquine and chloroquine have come under intense scrutiny over the past six months as they have been proposed as treatments for COVID-19. It is widely quoted and stated that the 4-aminoquinolines chloroquine and hydroxychloroquine cause oxidant hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency, yet there is no convincing evidence for this claim, and there is substantial evidence against it. X-linked G6PD deficiency is the most common human enzymopathy.

Tutankhamun's Antimalarial Drug for Covid-19

November 4, 2020 - 10:28 -- Open Access
Author(s): 
Sommer AP, Försterling HD, Sommer KE
Reference: 
Drug Res (Stuttg). 2020 Oct 30

Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. Current efforts to treat Covid-19 are based on this strategy. The first drugs used in patients infected with SARS-CoV-2 were antimalarial drugs. It is their mechanism of action, i. e., rise in endosomal pH, which recommends them against the new coronavirus.

The impact of COVID-19 pandemic on malaria elimination

October 31, 2020 - 09:28 -- Open Access
Author(s): 
Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K
Reference: 
Parasite Epidemiol Control. 2020 Oct 20:e00187

SARS-CoV-2 has spread throughout the world and become the cause of the infectious coronavirus disease 2019 (COVID-19). As low- and middle-income countries shift increasingly to focus on identifying and treating COVID-19, questions are emerging about the impact this shift in focus will have on ongoing efforts to control other infectious diseases, such as malaria.

Pages

Subscribe to RSS - Covid-19